Gene

CRKL

CRK like proto-oncogene, adaptor protein

Explore in graph →CI-GENE-00042239HGNC:2363 ENSG00000099942 NCBI 1399 CIViC Approved

Curated evidence

Clinical evidence (2)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CRKL Amplification2
Dasatinib	Malignant Gastric Neoplasm	Predictive	D	Supports Sensitivity Response	3	submitted	EID6398 CRKL amplification is observed in a subset of gastric cancers. MKN74 cells with CRKL amplification were responsive to the dual Src/BCR-ABL kinase inhibitor Dasatinib, likely via the inhibition of CRKL… (full text at CIViC) PMID 22591714 · Natsume et al., 2012 · Open in CIViC	civic
Gefitinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Resistance	4	submitted	EID6397 CRKL is an oncogene in a subset of NSCLC. Overexpression of CRKL induces cell transformation and resistance to epidermal growth factor receptor inhibitor treatment and suggest that therapeutic interve… (full text at CIViC) PMID 22586683 ·

Cohorts

Alteration frequency by cohort (14)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved14 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Bladder Cancer (Columbia University/MSK, Cell 2018) bladder_columbia_msk_2018	unmapped	Ssm	5	130	3.8%

Literature

Linked publications (0)

Data not yet available

No publication linked to this gene yet.